| Trial Acronym | DREAM |
| Trial Title | Determining the Role of Synthetic Cannabinoids in Eye Pressure And Tolerability Measurements (DREAM) |
| Clinical Area | Ophthalmology |
| Trial Status | Set Up |
| Trial Registration |
-
Recruitment
Recruitment Target 10 Date Open to Recruitment Recruitment Date Closed to Recruitment -
Trial Design
Trial Design A pilot, randomised, double-masked, placebo-controlled, single site, cross-over trial Study Aim The study aims to assess the preliminary efficacy and safety of a peripherally selective, synthetic cannabinoid (ART27.13), given orally, to reduce intraocular pressure (IOP) in patients with ocular hypertension or early primary open angle glaucoma. -
Chief Investigator (CI)
Chief Investigator Professor Augusto Azuara-Blanco, Queen’s University Belfast Email a.azuara-blanco@qub.ac.uk -
Sponsor(s) & Funder(s)
Sponsor Belfast Health and Social Care Trust Funder Glaucoma UK Public Health Agency (PHA), Health and Social Care (HSC) Research & Development Division, Northern Ireland